The research, led by Yeeshu Kumar and Sungjune Park of Sungkyunkwan University together with colleagues at Jeonbuk National University and the University of Seoul, addresses a long-standing bottleneck in wearable bioelectronics. Hydrogels have long been attractive candidates for skin-mounted sensors because their softness and water content resemble biological tissue, making them comfortable and biocompatible. Yet in practice they have struggled to earn clinical trust. They dehydrate over time, they are mechanically fragile, and their adhesion to skin is inconsistent, all of which degrade the delicate electrical contact between device and body.

The physics of the problem is unforgiving. Human electrophysiological signals occupy a low-frequency band, roughly 0.1 to 100 Hz, which is precisely where the skin-electrode interface is most hostile. High impedance at that interface attenuates the tiny biosignals before they ever reach the amplifier, while motion artifacts and ambient electrical noise pile on top. The result is the familiar hiss and drift that plagues consumer fitness bands and, more seriously, undermines diagnostic-grade monitoring. Achieving high-quality signal acquisition in this lower frequency range is especially critical, the authors note, because signal quality deteriorates sharply when skin-electrode impedance rises.

The Korean team’s solution is a hybrid material they call PeLM-CH: a conductive hydrogel incorporating pectin-encapsulated liquid metal particles, subsequently doped with an ionically conductive salt solution. Each component plays a distinct role. The liquid metal, typically a gallium-based alloy, contributes metallic conductivity, while the doped hydrogel matrix supplies ionic conductivity. By embedding both conduction pathways in a single soft material, the electrode can shuttle charge efficiently across the skin boundary without the rigid, dry metal contacts that irritate skin and lose contact as the body moves.

The pectin wrapper is the clever part. Pectin, a polysaccharide naturally found in plant cell walls, serves as a biocompatible shell around each liquid metal nanoparticle. This encapsulation stabilizes the particles within the hydrogel matrix, preventing them from coalescing or leaching while preserving the tissue-friendly character of the gel. The combination yields an electrode that is simultaneously soft and stretchable like skin, electrically conductive like metal, and stable enough for extended wear. The dual conduction mechanism, metallic from the liquid metal cores and ionic from the salt-doped gel, produces what the researchers describe as an appreciable decrease in skin-electrode impedance across the electrophysiological bandwidth.

The payoff shows up directly in signal quality. When the PeLM-CH electrodes were used to record ECG, the signal-to-noise ratio reached 15.05 dB; for EMG recordings it climbed to 20.98 dB. Those figures matter because signal-to-noise ratio is the fundamental currency of biosignal acquisition: every additional decibel represents a cleaner waveform from which algorithms and clinicians can extract heart rhythms, muscle activation patterns, and early warning signs of pathology. The improved performance is attributed to the electrode’s excellent skin conformity and relatively low interfacial impedance, which together allow faint biosignals to pass through with minimal loss and contamination.

Conformability deserves particular attention. Rigid electrodes make point contact with the uneven, microscopically rough surface of skin, concentrating pressure and current into small spots. A hydrogel electrode, by contrast, can deform to follow the skin’s contours, spreading the contact area and lowering the effective impedance. The pectin-liquid metal particles reinforce this effect by keeping the material conductive even as it stretches and flexes. The authors highlight that the PeLM-CH gel electrodes excel in clean, high-precision electrophysiological monitoring precisely because of this combination of skin conformity and low interfacial impedance in the frequency band where biosignals live.

The work also positions itself as a direct answer to the limitations of conventional gel electrodes, the sticky, wet pads used in hospitals for decades. Standard clinical electrodes rely on abrasive skin preparation and conductive paste that dries out within hours, making them poorly suited to continuous ambulatory monitoring. By embedding both the conductive elements and the adhesive, conformable interface into a single hydrogel, the new design points toward electrodes that could be worn for longer periods without reapplication, a prerequisite for the continuous cardiac and neuromuscular monitoring that next-generation healthcare envisions.

The implications extend beyond cardiology and muscle monitoring. Electrophysiological sensing underpins brain-computer interfaces, sleep studies, rehabilitation feedback, and the growing ecosystem of remote patient monitoring. Any platform that depends on reading the body’s faint electrical language benefits from a quieter, more stable skin interface. A material that combines biocompatibility, mechanical softness, dual metallic and ionic conduction, and resistance to dehydration could become a foundational building block for such systems, particularly as wearable devices are asked to deliver clinical-grade data outside the clinic.

The study, which was supported by grants from the National Research Foundation of Korea funded by the Korean government’s Ministry of Science and ICT, was published open access, allowing researchers worldwide to build on the results. The authors declare no competing interests, and the work involved collaborators from Sungkyunkwan University’s School of Chemical Engineering and its SKKU National Lab for Intelligent Energy Solution Technology, the spin-off company Wearable Fluidic, Jeonbuk National University’s Department of Electronic Engineering, and the University of Seoul’s Department of Intelligent Semiconductor Engineering. As wearable bioelectronics race toward mainstream medicine, the humble electrode, the point where silicon meets skin, may prove to be the decisive frontier, and liquid metal nanoparticles wrapped in fruit-derived polysaccharide may be an unlikely but potent weapon in that fight.

Subject of Research: Liquid metal-pectin nanoparticle hydrogel electrodes for wearable electrophysiological signal acquisition

Article Title: Liquid metal‒pectin polysaccharide nanoparticles integrated hydrogel epidermal electrodes for enhanced electrophysiological signal acquisition

Article References: Kumar, Y., Li, X., Bhuyan, P., Zhang, Q., Singh, M., Bae, H., Kim, T., & Park, S. (2026). Liquid metal‒pectin polysaccharide nanoparticles integrated hydrogel epidermal electrodes for enhanced electrophysiological signal acquisition. Advanced Composites and Hybrid Materials. https://doi.org/10.1007/s42114-026-02077-y

Image Credits: AI Generated

DOI: 10.1007/s42114-026-02077-y

Keywords: wearable bioelectronics, liquid metal nanoparticles, pectin, hydrogel electrodes, electrophysiological monitoring, ECG, EMG, skin-electrode impedance, signal-to-noise ratio, biomedical materials, soft materials, epidermal sensing

The stakes of this debate are unusually high. REM sleep behavior disorder, the clinical condition that arises when dream enactment accompanies loss of REM atonia, is now recognized as one of the most powerful early warning signs in all of medicine. Longitudinal cohort studies, including the landmark observational work by Alex Iranzo and colleagues published in The Lancet Neurology, followed patients diagnosed with idiopathic REM sleep behavior disorder, meaning cases with no obvious cause, and found that a large proportion went on to develop Parkinson’s disease or dementia with Lewy bodies, with post-mortem examination in some cases confirming synuclein pathology, the same protein abnormality that underlies those disorders. A subsequent multicenter study led by Ronald Postuma and an international team, published in the journal Brain, confirmed across dozens of centers that idiopathic REM sleep behavior disorder carries a substantial risk of incident dementia and parkinsonism over time. In practical terms, a polysomnography report showing REM sleep without atonia can set in motion years of anxious monitoring, counseling about future neurodegeneration, and even screening for enrollment in preventive drug trials targeting alpha-synuclein before symptoms emerge.

Into this high-stakes diagnostic arena steps a confounder that sleep clinicians have wrestled with for years: antidepressant medication. Since the early 2000s, accumulating evidence has linked the most widely prescribed antidepressants, particularly selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors, with both REM sleep behavior disorder symptoms and the underlying electrophysiological abnormality of REM sleep without atonia. The mechanisms are thought to involve serotonergic and noradrenergic modulation of the brainstem circuitry that governs REM atonia, effectively interfering with the switch that paralyzes the dreaming body. Postuma and colleagues raised the central question in a 2013 paper in the journal Sleep, asking whether antidepressant-associated REM sleep behavior disorder is an isolated side effect of the drugs or a neurodegenerative signal, a medication unmasking a process that was already underway. That question has never been fully resolved, and it sits at the heart of the new letter.

The letter responds directly to a recent quantitative study by Joumana Ahdab, Claudio Rodriguez, Margaret Grigg-Damberger, and colleagues, published in the same journal, which examined how different antidepressant medications have differential effects on REM sleep without atonia when it is quantified by chin and upper extremity electromyography. That work matters because the measurement itself is not straightforward. Polysomnography scoring of REM sleep without atonia depends on which muscles are sampled, how much electrical activity is counted as excessive, and which scoring rules are applied. The chin EMG channel is the traditional standard, but abnormal movements in REM sleep behavior disorder often manifest most dramatically in the limbs, and studies have shown that adding upper extremity EMG channels can substantially increase detection. Ahdab and colleagues’ finding that specific antidepressants differ in how much they elevate muscle tone during REM sleep, and that the effect varies depending on whether chin or arm muscles are measured, adds a crucial layer of nuance to a diagnostic system that often treats REM sleep without atonia as a binary yes-or-no finding.

Munir and his coauthors use this new evidence to argue for an expanded interpretation of the phenomenon. The core of their argument is that REM sleep without atonia in an antidepressant user cannot be read through the same lens as the same finding in a medication-free patient. If different drugs push the EMG signal in different directions, and if the choice of muscle group changes the result, then a single polysomnographic reading in a person taking, say, an SSRI may reflect a pharmacological effect on brainstem motor control rather than an early degenerative process. Interpreting such a finding as automatically equivalent to idiopathic REM sleep behavior disorder risks mislabeling patients, generating unwarranted fear of impending Parkinson’s disease or dementia, and potentially steering people away from effective psychiatric treatment out of alarm about their sleep study results.

At the same time, the letter’s authors are careful not to swing the pendulum too far in the other direction, because dismissing REM sleep without atonia in antidepressant users as a harmless side effect carries its own dangers. The 2013 Postuma analysis in Sleep found evidence pointing in both directions: antidepressant-associated REM sleep behavior disorder shares features with the idiopathic form, and some researchers have proposed that the medications may act as an unmasking agent, revealing subclinical neurodegeneration that would otherwise have remained silent for years. Under this model, a person whose brainstem inhibitory circuits are already being eroded by early synuclein disease has less reserve to resist the atonia-suppressing effects of serotonergic drugs, so the medication does not create the vulnerability but exposes it. If that model is correct, then REM sleep without atonia in an antidepressant user may still be a meaningful prognostic sign, and simply attributing it to the prescription would mean missing an opportunity for early surveillance.

The practical implications for clinical practice are considerable. Sleep physicians scoring a polysomnogram currently face a genuine interpretive dilemma when the patient’s medication list includes an antidepressant. Guidelines for REM sleep behavior disorder diagnosis do not fully account for drug effects on quantitative EMG measures, and there is no established algorithm for distinguishing pharmacological REM sleep without atonia from a neurodegenerative prodrome. The letter suggests that interpretation should be broadened to incorporate the medication context explicitly: which antidepressant the patient is taking, at what dose, for how long, whether the abnormal muscle tone is confined to the chin or extends to the limbs, and whether there is actual dream enactment behavior rather than isolated EMG abnormality. A finding of elevated chin tone alone in a patient who recently started a serotonergic antidepressant and has never acted out a dream is a very different clinical entity from violent nocturnal behaviors in a long-term user with limb movements and autonomic or olfactory changes suggestive of early parkinsonism.

The letter also underscores a broader lesson about how biomarkers travel from the research laboratory into everyday medicine. Quantitative REM atonia measures were developed and validated largely in cohorts carefully selected to answer specific research questions, often excluding people taking psychotropic medications precisely because those drugs confound the signal. When those same measures are applied in routine clinical polysomnography, where antidepressant use is common and often unremarked, the interpretive framework does not automatically come along with the measurement. The Islamabad authors’ contribution is to insist that the field close this gap, developing medication-aware reference ranges and interpretive standards so that a polysomnographic number means the same thing regardless of the patient’s pharmacy. Until that happens, they argue, clinicians should treat REM sleep without atonia in antidepressant users as a finding requiring nuanced judgment rather than a fixed diagnostic verdict.

What makes this debate resonate beyond the sleep laboratory is its window into the brain’s chemistry of dreaming. The fact that a daily pill for depression can loosen the grip of the paralysis that normally binds us to the mattress is a vivid reminder that the boundary between the dreaming mind and the waking body is actively maintained by specific neurotransmitter systems, and that those systems can be nudged by the medicines we take for entirely different purposes. Whether that nudging is benign, or whether it occasionally illuminates a disease process smoldering years before its first tremor, remains one of the most consequential open questions in sleep medicine. The letter by Munir, Imran, and Faraz does not settle it, but it makes a persuasive case that the answer will not come from treating all REM sleep without atonia as one thing. As antidepressant use continues to rise worldwide and as preventive trials for synucleinopathies move closer to reality, getting this interpretation right will determine who is told to worry, who is reassured, and who is offered a genuine head start against diseases that medicine has so far only been able to diagnose too late.

Subject of Research: REM sleep without atonia in antidepressant users and its implications for REM sleep behavior disorder diagnosis

Article Title: Expanding the interpretation of REM sleep without atonia in antidepressant users

Article References: Munir, A. B., Imran, H., & Faraz, N. (2026). Expanding the interpretation of REM sleep without atonia in antidepressant users. Journal of Clinical Sleep Medicine, 22(1), Article 147. https://doi.org/10.1007/s44470-026-00167-8

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00167-8

Keywords: REM sleep, REM sleep behavior disorder, antidepressants, polysomnography, sleep medicine, neurodegeneration, Parkinson's disease, dementia, SSRIs, psychopharmacology, EMG, sleep disorders